|
1
|
Casanova M, Özyar E, Patte C, Orbach D,
Ferrari A, Veyrat-Follet C, Errihani H, Pan J, Zhang L, Shen L, et
al: International randomized phase 2 study on the addition of
docetaxel to the combination of cisplatin and 5-fluorouracil in the
induction treatment for nasopharyngeal carcinoma in children and
adolescents. Cancer Chemother Pharmacol. 77:289–298. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen Y, Liu MZ, Liang SB, Zong JF, Mao YP,
Tang LL, Guo Y, Lin AH, Zeng XF and Ma J: Preliminary results of a
prospective randomized trial comparing concurrent chemoradiotherapy
plus adjuvant chemotherapy with radiotherapy alone in patients with
locoregionally advanced nasopharyngeal carcinoma in endemic regions
of china. Int J Radiat Oncol Biol Phys. 71:1356–1364. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li JG, Yuan X, Zhang LL, Tang YQ, Liu L,
Chen XD, Gong XC, Wan GF, Liao YL, Ye JM and Ao F: A randomized
clinical trial comparing prophylactic upper versus whole-neck
irradiation in the treatment of patients with node-negative
nasopharyngeal carcinoma. Cancer. 119:3170–3176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao M, Luo R, Liu Y, Gao L, Fu Z, Fu Q,
Luo X, Chen Y, Deng X, Liang Z, et al: miR-3188 regulates
nasopharyngeal carcinoma proliferation and chemosensitivity through
a FOXO1-modulated positive feedback loop with
mTOR-p-PI3K/AKT-c-JUN. Nat Commun. 7:113092016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng D, Zhu G, Liao S, Yi W, Luo G, He J,
Pei Z, Li G and Zhou Y: Dysregulation of the PI3K/Akt signaling
pathway affects cell cycle and apoptosis of side population cells
in nasopharyngeal carcinoma. Oncol Lett. 10:182–188.
2015.PubMed/NCBI
|
|
6
|
Viana LR and Gomes-Marcondes MC: A
leucine-rich diet modulates the tumor-induced down-regulation of
the MAPK/ERK and PI3K/Akt/mTOR signaling pathways and maintains the
expression of the ubiquitin-proteasome pathway in the placental
tissue of NMRI mice. Biol Reprod. 92:492015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wong CH, Loong HH, Hui CW, Lau CP, Hui EP,
Ma BB and Chan AT: Preclinical evaluation of the PI3K-mTOR dual
inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal
carcinoma. Invest New Drugs. 31:1399–1408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tasioudi KE, Sakellariou S, Levidou G,
Theodorou D, Michalopoulos NV, Patsouris E, Korkolopoulou P and
Saetta AA: Immunohistochemical and molecular analysis of
PI3K/AKT/mTOR pathway in esophageal carcinoma. APMIS. 123:639–647.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shin SY, Kim CG, Jung YJ, Lim Y and Lee
YH: The UPR inducer DPP23 inhibits the metastatic potential of
MDA-MB-231 human breast cancer cells by targeting the
Akt-IKK-NF-κB-MMP-9 axis. Sci Rep. 6:341342016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng H, Dai W, Cheung AK, Ko JM, Kan R,
Wong BW, Leong MM, Deng M, Kwok TC, Chan JY, et al: Whole-exome
sequencing identifies multiple loss-of-function mutations of NF-κB
pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci
USA. 113:pp. 11283–11288. 2016; View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang L and Huang J: Oxymatrine inhibits
epithelial-mesenchymal transition through regulation of NF-κB
signaling in colorectal cancer cells. Oncol Rep. 36:1333–1338.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin B, Li D and Zhang L: Oxymatrine
mediates Bax and Bcl-2 expression in human breast cancer MCF-7
cells. Pharmazie. 71:154–157. 2016.PubMed/NCBI
|
|
13
|
Peng PJ, Ou XQ, Chen ZB, Liao H, Peng YL,
Wang SY, Zhang HY and Lin Z: Multicenter phase II study of
capecitabine combined with nedaplatin for recurrent and metastatic
nasopharyngeal carcinoma patients after failure of cisplatin-based
chemotherapy. Cancer Chemother Pharmacol. 72:323–328. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Sun Y, Liang SB, Zong JF, Li WF,
Chen M, Chen L, Mao YP, Tang LL, Guo Y, et al: Progress report of a
randomized trial comparing long-term survival and late toxicity of
concurrent chemoradiotherapy with adjuvant chemotherapy versus
radiotherapy alone in patients with stage III to IVB nasopharyngeal
carcinoma from endemic regions of China. Cancer. 119:2230–2238.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Zhao L, Huang P, Wu J, Wang F,
Huang Y and Zhang L: Open-label, single-arm phase II study of
pemetrexed in the treatment of patients with recurrent or
metastatic nasopharyngeal carcinoma who have had prior
platinum-based chemotherapy. Cancer Chemother Pharmacol.
70:611–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bourouba M, Benyelles-Boufennara A, Terki
N, Baraka-Kerboua E, Bouzid K and Touil-Boukoffa C: Epidermal
growth factor receptor (EGFR) abundance correlates with p53 and
Bcl-2 accumulation and patient age in a small cohort of North
African nasopharyngeal carcinoma patients. Eur Cytokine Netw.
22:38–44. 2011.PubMed/NCBI
|
|
17
|
Kao CL, Cho J, Lee YZ, Cheng YB, Chien CY,
Hwang CF, Hong YR, Tseng CN and Cho CL: Ethanolic extracts of
pluchea indica induce apoptosis and antiproliferation effects in
human nasopharyngeal carcinoma cells. Molecules. 20:11508–11523.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu C, Huang W, Guo Y, Xia P, Sun X, Pan X
and Hu W: Oxymatrine inhibits the proliferation of prostate cancer
cells in vitro and in vivo. Mol Med Rep. 11:4129–4134. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu M, Cheung CC, Chow C, Lun SW, Cheung ST
and Lo KW: Overexpression of PIN1 enhances cancer growth and
aggressiveness with cyclin D1 induction in EBV-associated
nasopharyngeal carcinoma. PLoS One. 11:e01568332016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liao D, Wu Y, Pu X, Chen H, Luo S, Li B,
Ding C, Huang GL and He Z: Cyclin D1 G870A polymorphism and risk of
nasopharyngeal carcinoma: A case-control study and meta-analysis.
PLoS One. 9:e1132992014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng G, Cao RB, Li YH, Zou ZW, Huang J and
Ding Q: Alterations of cell cycle control proteins SHP-1/2, p16,
CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma
cells. Mol Med Rep. 10:1709–1716. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Bi T, Wang Z, Wu G, Qian L, Gao Q
and Shen G: Oxymatrine synergistically enhances antitumor activity
of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.
Apoptosis. 21:1398–1407. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu X, Zhen Y, Yang H, Wang H, Zhou Y, Wang
E, Marincola FM, Mai C, Chen Y, Wei H, et al: Loss of connective
tissue growth factor as an unfavorable prognosis factor activates
miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in
nasopharyngeal carcinoma. Cell Death Dis. 4:e6342013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuen JW, Chung GT, Lun SW, Cheung CC, To
KF and Lo KW: Epigenetic inactivation of inositol polyphosphate
4-phosphatase B (INPP4B), a regulator of PI3K/AKT signaling pathway
in EBV-associated nasopharyngeal carcinoma. PLoS One.
9:e1051632014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen J: Roles of the PI3K/Akt pathway in
Epstein-Barr virus-induced cancers and therapeutic implications.
World J Virol. 1:154–161. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu DD, Zhang J, Deng W, Yip YL, Lung HL,
Tsang CM, Law WT, Yang J, Lau VM, Shuen WH, et al: Significance of
NF-κB activation in immortalization of nasopharyngeal epithelial
cells. Int J Cancer. 138:1175–1185. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin ML, Lu YC, Chung JG, Wang SG, Lin HT,
Kang SE, Tang CH, Ko JL and Chen SS: Down-regulation of MMP-2
through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin
leads to inhibition of nasopharyngeal carcinoma cell invasion. Mol
Carcinog. 49:783–797. 2010.PubMed/NCBI
|
